Protein-losing enteropathy in an infant with severe atopic dermatitis

Severe atopic dermatitis (AD) may lead to various complications such as hypoproteinaemia. We describe the case of a 7-month-old male infant with severe AD complicated with protein-losing enteropathy (PLE). He was diagnosed with AD at 2 months of age; however, because of familial steroid phobia, topical corticosteroids were not administered. At 7 months of age, he was admitted to our hospital for decreased feeding, diarrhoea, reduced urine volume and recurrent vomiting. Class 3 topical corticosteroid treatment was initiated. On day 3, eczema had almost resolved. However, serum protein levels had not improved; oliguria persisted and oedema worsened. Serum albumin scintigraphy revealed radioisotopes in the distal duodenum, leading to PLE diagnosis. Systemic prednisolone and albumin were administered, with no PLE relapse after discontinuation. To our knowledge, only two infant PLE cases associated with AD were reported to date. PLE should be considered in patients with severe AD and persistent hypoproteinaemia.

Download Full-text

Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: A randomized, double-blind trial

Journal of Dermatological Treatment ◽

10.3109/09546630903410158 ◽

2010 ◽

Vol 21 (3) ◽

pp. 157-166 ◽

Cited By ~ 11

Author(s):

Michael Meurer ◽

Lawrence F. Eichenfield ◽

Vincent Ho ◽

Paul C. Potter ◽

Thomas Werfel ◽

...

Keyword(s):

Atopic Dermatitis ◽

Topical Corticosteroid ◽

Treatment Regimen ◽

Corticosteroid Treatment ◽

Severe Atopic Dermatitis ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial ◽

Paediatric Patients

Download Full-text

Clinical and Therapeutic Trial for the Efficacy of Narrow Band - UVB Phototherapy versus Systemic Therapy in Moderate and Severe Atopic Dermatitis of the Adult

Acta Medica Marisiensis ◽

10.2478/amma-2018-0003 ◽

2018 ◽

Vol 64 (1) ◽

pp. 17-21

Author(s):

Gyula Laszlo Fekete ◽

László Fekete

Keyword(s):

Atopic Dermatitis ◽

Side Effects ◽

Systemic Therapy ◽

Systemic Corticosteroid ◽

Corticosteroid Treatment ◽

Serum Levels ◽

Severe Atopic Dermatitis ◽

Therapeutic Trial ◽

Group I ◽

Uvb Phototherapy

AbstractObjectives: The aim of this clinical and therapy study was to evaluate the efficacy of NB-UVB phototherapy versus systemic therapy in moderate-to-severe atopic dermatitis of the adult.Material and methods: The subjects of the study were divided into two groups of 25 adult patients with moderate and severe atopic dermatitis according to the inclusion criteria. The first group of 25 patients were treated with systemic corticosteroids while the second group of 25 patients were treated with NB-UVB phototherapy. At the end of the study, after all the data were centralized, we performed a statistical analysis of the results, comparing the two groups as well as the efficacy of the different therapies.Results: In group I the clinical efficacy of the systemic corticosteroid treatment was achieved, on average, at 4 weeks in patients with moderate atopic dermatitis and at 6 weeks in patients with severe atopic dermatitis. In group II the clinical effecacy of NB-UVB phototherapy was achieved, on average, at 6 weeks for patients with moderate atopic dermatitis and at 8 weeks for those with the severe form. In both groups, the total IgE serum levels were elevated at the beginning, and they became normal throughout the clinical improvement. Remarkable therapy-related side effects were found in the first study group.Conclusion: We conclude that NB-UVB phototherapy had similar efficacy in treating moderate-to-severe atopic dermatitis with minimal side effects compared to systemic corticosteroid therapy.

Download Full-text